140 related articles for article (PubMed ID: 9818315)
21. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
22. Non-ionic Gd-based MRI contrast agents are optimal for encapsulation into phosphatidyldiglycerol-based thermosensitive liposomes.
Hossann M; Wang T; Syunyaeva Z; Wiggenhorn M; Zengerle A; Issels RD; Reiser M; Lindner LH; Peller M
J Control Release; 2013 Feb; 166(1):22-9. PubMed ID: 23246469
[TBL] [Abstract][Full Text] [Related]
23. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging.
Unger EC; Winokur T; MacDougall P; Rosenblum J; Clair M; Gatenby R; Tilcock C
Radiology; 1989 Apr; 171(1):81-5. PubMed ID: 2928550
[TBL] [Abstract][Full Text] [Related]
24. Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver.
Kabalka GW; Davis MA; Holmberg E; Maruyama K; Huang L
Magn Reson Imaging; 1991; 9(3):373-7. PubMed ID: 1881256
[TBL] [Abstract][Full Text] [Related]
25. Molecular imaging of angiogenesis to delineate the tumor margins in glioma rat model with endoglin-targeted paramagnetic liposomes using 3T MRI.
Qiu LH; Zhang JW; Li SP; Xie C; Yao ZW; Feng XY
J Magn Reson Imaging; 2015 Apr; 41(4):1056-64. PubMed ID: 24677456
[TBL] [Abstract][Full Text] [Related]
26. Choice of metal ion and formulation concentration for first-pass brain perfusion studies with magnetic resonance imaging at 1.5 tesla.
Runge VM; Wells JW
Invest Radiol; 1996 Jul; 31(7):395-400. PubMed ID: 8818779
[TBL] [Abstract][Full Text] [Related]
27. Relaxivity of liposomal paramagnetic MRI contrast agents.
Strijkers GJ; Mulder WJ; van Heeswijk RB; Frederik PM; Bomans P; Magusin PC; Nicolay K
MAGMA; 2005 Sep; 18(4):186-92. PubMed ID: 16155762
[TBL] [Abstract][Full Text] [Related]
28. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
29. Liposomal Gd-DTPA: preparation and characterization of relaxivity.
Tilcock C; Unger E; Cullis P; MacDougall P
Radiology; 1989 Apr; 171(1):77-80. PubMed ID: 2928549
[TBL] [Abstract][Full Text] [Related]
30. Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen.
Kabalka G; Buonocore E; Hubner K; Moss T; Norley N; Huang L
Radiology; 1987 Apr; 163(1):255-8. PubMed ID: 3454163
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents.
Marinelli ER; Neubeck R; Song B; Wagler T; Ranganathan RS; Sukumaran K; Wedeking PW; Nunn A; Runge VM; Tweedle MF
Invest Radiol; 2000 Jan; 35(1):8-24. PubMed ID: 10639032
[TBL] [Abstract][Full Text] [Related]
32. An intravascular MRI contrast agent based on Gd(DO3A-Lys) for tumor angiography.
Yang CT; Chandrasekharan P; He T; Poh Z; Raju A; Chuang KH; Robins EG
Biomaterials; 2014 Jan; 35(1):327-36. PubMed ID: 24138829
[TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of two membrane-based liposomal MRI contrast agents.
Karlik S; Florio E; Grant CW
Magn Reson Med; 1991 May; 19(1):56-66. PubMed ID: 2046538
[TBL] [Abstract][Full Text] [Related]
34. Liposomes with conjugates of a calix[4]arene and a Gd-DOTA derivative on the outside surface; an efficient potential contrast agent for MRI.
Schühle DT; van Rijn P; Laurent S; Vander Elst L; Muller RN; Stuart MC; Schatz J; Peters JA
Chem Commun (Camb); 2010 Jun; 46(24):4399-401. PubMed ID: 20467663
[TBL] [Abstract][Full Text] [Related]
35. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging.
Kamaly N; Kalber T; Ahmad A; Oliver MH; So PW; Herlihy AH; Bell JD; Jorgensen MR; Miller AD
Bioconjug Chem; 2008 Jan; 19(1):118-29. PubMed ID: 17985841
[TBL] [Abstract][Full Text] [Related]
36. Heat-activated liposomal MR contrast agent: initial in vivo results in rabbit liver and kidney.
McDannold N; Fossheim SL; Rasmussen H; Martin H; Vykhodtseva N; Hynynen K
Radiology; 2004 Mar; 230(3):743-52. PubMed ID: 14764890
[TBL] [Abstract][Full Text] [Related]
37. Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress.
Unger E; Needleman P; Cullis P; Tilcock C
Invest Radiol; 1988 Dec; 23(12):928-32. PubMed ID: 3203995
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study.
de Smet M; Heijman E; Langereis S; Hijnen NM; Grüll H
J Control Release; 2011 Feb; 150(1):102-10. PubMed ID: 21059375
[TBL] [Abstract][Full Text] [Related]
39. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
[TBL] [Abstract][Full Text] [Related]
40. Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.
Xiao Y; Xue R; You T; Li X; Pei F; Wang X; Lei H
Carbohydr Res; 2014 Aug; 395():9-14. PubMed ID: 24995911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
